azlocillin
Trade name: azlin
Small moleculeapproved
Azlocillin is a semisynthetic penicillin with broad spectrum of anti-bacterial action. The drug is effective against gram-negative and gram-positive infections and acts by inhibition of penicillin-binding protein (PBP)-dependent bacterial cell wall synthesis. Azlocillin was marketed in the USA under the name Azlin (sodium salt), however, its approval was discontinued. — NCATS
Clinical trial activity
11 trials · 8 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
11
Phase 3
9
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00104520)
Timeline
Indications
Approved for
Mechanism of action
- Penicillin-binding proteinINHIBITOR
Penicillin-binding protein inhibitor
Approval history
- approved—
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O- Mol. weight
- 461.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1537 ↗
- WikipediaAzlocillin ↗
- NCATSHUM6H389W0 ↗
- ChEMBLCHEMBL1201041 ↗
Also known as
- (2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- azli
- azlin
- azlin
- azlin
- azlocilina
- azlocilina
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocillin
- azlocilline
- azlocilline
- azlocillin sodium
- azlocillin sodium
- azlocillin sodium
- azlocillin sodium
- azlocillin sodium salt
- azlocillinum
- azlocillinum
- securopen
- securopen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01641822 | Phase 3 | Dec 1, 2012 | Gilead Sciences |
| NCT01404234 | Phase 3 | Dec 1, 2011 | Gilead Sciences |
| NCT01314716 | Phase 3 | Apr 1, 2011 | Georgetown University, Gilead Sciences |
| NCT01313624 | Phase 3 | Apr 1, 2011 | Gilead Sciences, Oregon Health and Science University |
| NCT01059565 | Phase 3 | Feb 1, 2010 | Gilead Sciences |
| NCT00805025 | Phase 2 | Dec 1, 2008 | Gilead Sciences |
| NCT00794586 | Phase 2 | Nov 1, 2008 | Gilead Sciences, University of Cincinnati |
| NCT00712166 | Phase 3 | May 1, 2008 | Gilead Sciences, University of Melbourne, University of Washington |
| NCT00128492 | Phase 3 | Aug 1, 2005 | Gilead Sciences |
| NCT00112359 | Phase 3 | May 1, 2005 | Corus Pharma, Gilead Sciences |
| NCT00104520 | Phase 3 | Feb 1, 2005 | Gilead Sciences, Ohio State University |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 11 | 11 | 2 | 2005 |
| Corus Pharma | For profit | 1 | 0 | 1 | 2005 |
| Georgetown University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1